Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin
- 15 November 1996
- Vol. 78 (10) , 2193-2198
- https://doi.org/10.1002/(sici)1097-0142(19961115)78:10<2193::aid-cncr22>3.0.co;2-t
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Placebos and Principles: A Trial of OndansetronAnnals of Internal Medicine, 1993
- Comparison of the 5-Hydroxytryptamine3(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced EmesisNew England Journal of Medicine, 1990
- Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and VomitingNew England Journal of Medicine, 1990
- Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy.Journal of Clinical Oncology, 1988
- Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trialCancer, 1987
- Antiemetic Efficacy of DexamethasoneNew England Journal of Medicine, 1984
- Intravenous MetoclopramideJAMA, 1982
- Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and VomitingNew England Journal of Medicine, 1981
- Delta-9-Tetrahydrocannabinol as an Antiemetic for Patients Receiving Cancer ChemotherapyAnnals of Internal Medicine, 1979
- Antiemetic Effect of Delta-9-Tetrahydrocannabinol in Patients Receiving Cancer ChemotherapyNew England Journal of Medicine, 1975